Spero Therapeutics, Inc. financial data

Symbol
SPRO on Nasdaq
Industry
Pharmaceutical Preparations
Location
675 Massachusetts Avenue, 14 Th Floor, Cambridge, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Spero Therapeutics, LLC (to 3/21/2017)
Latest financial report
10-Q - Q2 2024 - Aug 5, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 330 % -27.5%
Debt-to-equity 80 % +5.6%
Return On Assets -92.1 % -63.4%
Operating Margin 13.1 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 54M shares +2.57%
Common Stock, Shares, Outstanding 54M shares +2.73%
Entity Public Float 76M USD
Common Stock, Value, Issued 54K USD +1.89%
Weighted Average Number of Shares Outstanding, Basic 54M shares +2.64%
Weighted Average Number of Shares Outstanding, Diluted 54M shares +2.64%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 118M USD +118%
Revenue from Contract with Customer, Excluding Assessed Tax 695K USD -62.5%
Research and Development Expense 74M USD +80.8%
General and Administrative Expense 23.6M USD -11.1%
Operating Income (Loss) 15.6M USD -47.9%
Nonoperating Income (Expense) 4.5M USD +52.8%
Income Tax Expense (Benefit) 2.21M USD
Net Income (Loss) Attributable to Parent -17.9M USD -50.4%
Earnings Per Share, Basic 0.34 USD/shares +100%
Earnings Per Share, Diluted 0.34 USD/shares +100%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 63.5M USD -18.2%
Marketable Securities, Current 0 USD -100%
Assets, Current 122M USD +38.3%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 3.64M USD -21.6%
Other Assets, Noncurrent 434K USD -92.4%
Assets 150M USD +51.6%
Accounts Payable, Current 2.7M USD +106%
Employee-related Liabilities, Current 2.03M USD +21.9%
Liabilities, Current 45.6M USD +163%
Operating Lease, Liability, Noncurrent 3.21M USD -27.3%
Liabilities 69.4M USD +57.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -422M USD +3.98%
Stockholders' Equity Attributable to Parent 80.5M USD +46.9%
Liabilities and Equity 150M USD +51.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 5.94M USD
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 54M shares +2.73%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 5.94M USD
Deferred Tax Assets, Valuation Allowance 108M USD -6.02%
Deferred Tax Assets, Gross 108M USD -6.02%
Operating Lease, Liability 5.54M USD -16.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 22.8M USD +91.2%
Lessee, Operating Lease, Liability, to be Paid 6.58M USD -20.4%
Property, Plant and Equipment, Gross 3.62M USD 0%
Operating Lease, Liability, Current 1.73M USD +1.64%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.72M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.69M USD +24.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.03M USD -36.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.75M USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 25.6M USD -67.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.96M USD 0%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 0 USD -100%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%